DME payments durable after all
This article was originally published in The Gray Sheet
Executive Summary
Medicare rural health provisions - including an offsetting freeze in inflationary Medicare updates for durable medical equipment, application of deductibles and coinsurance for diagnostic lab tests and a reduction in the Average Wholesale Price for outpatient drugs - were removed from the Senate omnibus tax bill (S 1054) during conference negotiations (1"The Gray Sheet" May 19, 2003, In Brief). In a May 22 letter to Finance Committee Chairman Charles Grassley (R-Iowa), President Bush expresses his support for inclusion of the $25 bil. Medicare rural health payment increases in Medicare reform legislation. However, it is unlikely that the controversial offsets will remain on the table...
You may also be interested in...
Non-durable DME payments?
10-year freeze in consumer price index for durable medical equipment, orthotics and prosthetics is folded into omnibus tax package (S 1054) approved by the Senate May 15. The provision, along with language addressing application of deductibles and coinsurance for clinical diagnostic lab tests and a reduction of the Average Wholesale Price for outpatient drugs, is intended to offset $25 bil. in Medicare payment increases to rural health providers. Included in the bill's reimbursement enhancements is a two-year extension of "reasonable cost payments" for certain diagnostic tests delivered in sole community hospitals. Finance Committee Chairman Charles Grassley (R-Iowa) introduced the amendment, which cleared the Senate earlier in the day in an 86-12 vote...
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.